Please assess the completion status of the following clinical trial:

Trial Title: Growth Hormone, Cardiovascular Risk, and Visceral Adiposity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* For growth hormone measurement part (for men and women):~  1. For visceral adiposity arm: waist circumference greater than or equal to 88 cm for women or 102 cm for men, and BMI greater than or equal to 25 kg/m2~ 2. For lean controls: BMI 18.5 to 24.9 kg/m2~* For growth hormone treatment part (for men and women):~  1. Visceral adiposity (waist circumference greater than or equal to 88 cm for women and 102 for men, BMI greater than or equal to 25 kg/m2)~ 2. IGF-I within the lowest 2 quartiles for age and gender~ 3. Willingness to maintain current activity level and diet~Exclusion Criteria:~* Diabetes mellitus (fasting plasma glucose greater than 126 mg/dL or 2-hour post-oral glucose tolerance test \[OGTT\] plasma glucose greater than 200)~* Taking the following medications in the last 3 months: weight loss or lipid-lowering agents, medications to treat diabetes mellitus or pre-diabetes, oral contraceptives or estrogen-containing medications, other medications known to significantly affect weight~* Smoking~* Hematocrit below the lower limit of normal~* Amenorrhea for 3 months (in women)~* Pregnant or breastfeeding (in women)~* Polycystic ovary syndrome (in women)~* Weight that exceeds 280 pounds~* SGPT greater than 2 times the upper limit of normal~* History of malignancy, except for fully resolved basal cell carcinomas of the skin (Specific Aim 2 only)~* Radiation exposure greater than 1000 mrem over the last 12 months~* Previous diagnosis of cardiovascular disease~* History of pituitary or hypothalamic disease, brain radiation, or childhood growth hormone deficiency~* History of carpal tunnel syndrome that has not been surgically treated

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Male on GH (Type: EXPERIMENTAL): Participants received growth hormone replacement therapy. The starting dose was 2 micrograms/kg per day and they were titrated within the normal range based on blood levels.~Nutropin AQ growth hormone : Participants gave themselves injections of growth hormone every night for 6 months.
- Male on Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo.~Placebo Growth Hormone : Participants gave themselves injections of placebo every night for 6 months.
- Female on GH (Type: EXPERIMENTAL): Participants received growth hormone replacement therapy. The starting dose was 4 micrograms/kg per day and they were titrated within the normal range based on blood levels.~Nutropin AQ growth hormone : Participants gave themselves injections of growth hormone every night for 6 months.
- Female on Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo.~Placebo Growth Hormone : Participants gave themselves injections of placebo every night for 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).